Redhill Biopharma Ltd. (NASDAQ:RDHL)
Redhill Biopharma Ltd. (NASDAQ:RDHL) represented a move of 0 percent or $0.73 per share and closed its previous day trading session at $7.27. 0 Shares were traded in the last trading session with an Average Volume of 93.28 Million Shares. The stock currently has a Market Capitalization of 1.55 Billion.
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).
The stock traded between $ 4.30 and $11.49 over 1-Year time period showing its price to sales ratio of 172.37. Redhill Biopharma Ltd. (NASDAQ:RDHL) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-11.9 and 200-Day Simple Moving Average of $-0.17. Its Price to Free Cash Flow is 0 and Price to Book of 4.28.
Analyst’s recommended the stock as 1.8 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Redhill Biopharma Ltd. (NASDAQ:RDHL) reported its Actual EPS of $-0.4/share. The analysts offering Earnings Estimates for the company were believing that Redhill Biopharma Ltd. could bring EPS of $-0.41/share. The difference between Actual EPS and Estimated EPS was 0.01 Percent. Thus showing an Earnings Surprise of 2.4 Percent.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
In the last trading session, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) added its value by 0% closing at the price of $3. The stock currently has market capitalization of 62.31 Million, with average volume of 51.04 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is showing beta of 1.57. This particular value of beta suggests that Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has historically moved 157% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) is at $-0.42.
The stock currently has RSI of 36.1. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson’s disease. Brainstorm Cell Therapeutics is based in New York.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) topped its 52-week high price of $5.35 on 06/04/18 and 52-Week Low Price of $2.88 on 02/09/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 3.20% and monthly volatility of 4.10% respectively.